Dec 9 (Reuters) - BioNTech SE <22UAy.DE>::
*BIONTECH AND BRISTOL MYERS SQUIBB PRESENT FIRST GLOBAL PHASE 2 DATA FOR PD-L1XVEGF-A BISPECIFIC ANTIBODY PUMITAMIG SHOWING ENCOURAGING EFFICACY IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER
*PUMITAMIG PLUS CHEMOTHERAPY ACHIEVED CONFIRMED OBJECTIVE RESPONSE RATE $(CORR)$ OF 61.5%, UNCONFIRMED ORR (UORR) OF 71.8% AND DISEASE CONTROL RATE (DCR) OF 92.3% IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS
*DATA ARE CONSISTENT WITH PREVIOUSLY REPORTED DATA FROM 1L TNBC PHASE 1B/2 TRIAL CONDUCTED IN CHINA AND CONFIRM DOSE SELECTION FOR PIVOTAL PHASE 3 ROSETTA BREAST-01 TRIAL
*DATA WILL BE PRESENTED AT 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM ("SABCS")
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 09-DEC-202512:00:00.07 GMTDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments